Preliminary studies in the development of triamcionolone acetonide lipid nanocapsules.

MARÍA LINA FORMICA; GABRIELA VERONICA ULLIO GAMBIO; JEAN PIERRE BENOIT; SANTIAGO DANIEL PALMA

Córdoba

Congreso; 3ra Reunión Internacional de Ciencias Farmacéuticas; 2014

Facultad de Ciencias Químicas-Universidad Nacional de Córdoba

Triamcinolone acetonide (TAA) is a synthetic corticosteroid used to treat a broad spectrum of retinal diseases. The development of TAA dosage forms is limited due to its poor solubility in water and/or physiologically acceptable solvents1. The purpose of this work was to develop and characterize a novel lipid nanocapsule (LNC) formulation as drug delivery system for TAA. LNCs were prepared using an optimized phase inversion-based method2. Due to the poor solubility of TAA in the oily phase of the original formulation, two co-surfactants (captex® 500p -Glyceryl triacetate and oleic acid) in three proportions: 20, 30 and 50% were tested. The average particle size, polydispersity index (PI) and zeta potential were measured. Acceptable results were obtained only with a 20% of both co-surfactants. LNCs with captex® 500p leads to about (42.3±0.2) nm size nanoparticles with a narrow size distribution (PI less than 0.2) and a negative z potential (-4±1) mV while LNCs with oleic acid showed an average particle size of (37.0±0.5) nm and a PI below 0.1 with a negative z potential (-11 ±5) mV. The obtained formulations allow the encapsulation of TAA and it could be a potential strategy to treat several ocular diseases of the posterior segment by intravitreal route. Further studies will be carried out to test the encapsulation efficiency and the long-term stability of these formulations.